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In 2000, members of the Australian and New
Zealand Society of Palliative Medicine were
surveyed to compile a list of the medications
they considered essential in the practice of
palliative care and the indications for which
they were prescribed.1 A number of the drugs
that respondents highlighted were available
on the nationally subsidised Pharmaceutical
Benefits Scheme (PBS), such as morphine in
its indication for the management of cancer-
related pain and haloperidol for control of
delirium. However, many other medications
commonly used in palliative care were not
listed on the PBS (see tables 1 and 2) and
were therefore not freely available to patients
outside hospitals ie. those patients in
hospices, residential aged care facilities and in
the community. Midazolam, used for terminal
restlessness and hyoscine hydrobromide to
control end-stage respiratory secretions, were
two such agents used frequently and
effectively, but not available on the PBS.
One of the Standards for Providing Quality
Palliative Care for all Australians published by
Palliative Care Australia is that the needs and
wishes of patients, their caregivers and
families are acknowledged and used to guide
decision-making and care planning.2 The fact
that those patients choosing to remain at
home are obliged to buy many of their
essential medications at full cost profoundly
disadvantages patients who wish to die in the
community – potentially restricting any real
choices they may have in deciding about
some aspects of their care. Moreover, many
of these medications being prescribed in the
palliative care setting are being used ‘off-
licence’ for indications, routes of delivery and
doses not yet approved by the Therapeutics
Goods Administration (TGA).
These difficulties have been recognised and
acknowledged by the Department of Health
and Ageing and the Australian Government.
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Abstract
Many of the drugs commonly used in palliative care are not listed on the Pharmaceutical Benefits Scheme in Australia
and are therefore not freely available to patients outside the acute hospital system. In an attempt to address the
inequity faced by patients being cared for in the community or hospices, the Palliative Care Medicines Working Group
was established by the Australian Government. This has resulted in a separate palliative section within the Schedule
of Pharmaceutical Benefits Scheme which allows for authority prescribing of a number of medications that may be
required by a palliative care patient. This paper discusses the medications currently on this listing, the processes by
which they were selected and the ongoing efforts to broaden access to required medications.
Table 1. Top 25 drugs identified as being most useful in the
management of a number of symptoms1
Medication Indication PBS availability+
Morphine pain Y
dypsnoea N
Haloperidol delirium Y
Dexamethasone anorexia/cachexia Y
Midazolam terminal restlessness N
Metoclopramide nausea/vomiting Y
Clonazepam insomnia Y
Paracetamol pain Y
Amitriptyline neuropathic pain Y
Pamidronate hypercalcaemia Y
Cyclizine nausea/vomiting N
Hyoscine hydrobromide retained resp secretions N
Diazepam insomnia Y
Lorazepam insomnia N
Omeprazole dyspepsia Y
Chlorpromazine delirium Y
Fentanyl
– transdermal pain Y
– parenteral pain N
Spironolactone ascites Y
Ranitidine dyspepsia Y
Promethazine pruritis N
Frusemide fluid retention Y
Ondansetron nausea/vomiting* Y
Docusate/senna constipation N
Temazepam insomnia Y
Prednisolone anorexia Y
Methadone pain
– tablet Y
– liquid N
+ PBS listing for many of these drugs is general and not specific to
the indication noted.
* approved only for chemotherapy and radiotherapy induced
nausea/vomiting.
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Hence, a key area of the National Palliative Care
Program is to improve access to affordable medicines
through the PBS.
Improving access to medications
The Palliative Care Medicines Working Group (PCMWG)
was established by the Australian Government in an
attempt to remedy this situation. This expert group
comprises invited clinicians, pharmacists and
pharmaceutical industry representatives, along with
government and drug regulatory officers. Its aim is to
provide advice to the Australian Government on how to
improve access to and quality use of medicines in the
community. A communication sub-group has been
established to raise awareness within the primary health
care workforce of palliative care medicines already listed
on the PBS and ways to improve access to essential
medicines used in palliative care through a new PBS
framework.
The first successful initiative has been the inclusion of a
palliative care section within the PBS. This is the first
section ever created in the PBS for a specific patient
population. It allows for authority prescribing for those
people meeting the definition of a palliative care patient
and includes all patients with life-limiting disease (eg.
those with end-stage heart or renal failure or motor
neuron disease) (see box 1). It does not limit prescribing
to those felt to have a specified prognosis, but
rather focuses on maximising quality of life as
the primary intent of care. This section is
intended to complement and be used with the
general listings, but the indications cited are
often broader than those indications listed in
the general section. For example, while non
steroidal anti-inflammatory drugs (NSAIDs) are
authorised only for patients with pain
secondary to osteoarthritis in the general PBS
section, they can be prescribed for severe
pain of any aetiology to palliative care patients.
Similarly, a prescription of a prolonged course
of benzodiazepines is not restricted to
residents of an aged care facility who have
failed a trial of drug withdrawal. The restriction
on opioid prescribing for patients with non-
malignant disease has also been lessened.
While previously, opioids could only be
initiated in hospital, under a palliative care
authority they can also be started in the community. All
palliative care listings are “authority required”.
Continuing treatment beyond four months requires a
consultation with a specialist palliative care service, but
this can be in the form of a telephone call between the
general practitioner and a specialist or specialist service
and does not require a face-to-face patient visit.
Box 1. Definition of a palliative care patient for PBS
purposes 
It is important to note that the change sought is often
not only for any particular drug to be available, but also
for the specific indication, formulation and/or route of
delivery. A good example of this is clonazepam. The
drug previously had approval only for the treatment of
established epilepsy. The PCMWG has subsequently
gained approval so that the indication for clonazepam is
extended to include the prevention of epilepsy
(including myoclonus).
One criticism of the content of the palliative care section
as it currently stands is that it lists a relatively small
number of drugs (see table 3) and the ‘wish-list’ of those
practising palliative care remains
substantially longer. However, the
process of listing a drug on the
PBS is rigorous and is dependent
on the approval of a number of
committees, including the TGA
and the Pharmaceutical Benefits
Advisory Committee. The quality,
safety and efficacy of any drug
must be judged satisfactory prior
to any product registration and
any application for PBS listing. The
comparative safety, efficacy and
cost-effectiveness of the new
agent must then be assessed
against existing products and the
list price negotiated. Furthermore,
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“A patient with an active, progressive, far-advanced
disease for whom the prognosis is limited and the
focus of care is on quality of life.”
Table 2. Top 10 non-PBS listed drugs for the management of
common symptoms3
Medication Indication
Midazolam terminal restlessness
Cyclizine nausea/vomiting
Hyoscine hydrobromide respiratory secretions
Lorazepam insomnia
Fentanyl (injection) pain
Ondansetron non-chemo, RT nausea/vomiting
Docusate/senna constipation
Methadone (liquid) pain
Gabapentin neuropathic pain
Ketamine pain
Phenobarbitone terminal restlessness
Table 3. Drugs listed in the palliative care section to date
Benzydamine hydrochloride
Carmellose sodium
Hyoscine butylbromide (injection)
Promethazine hydrochloride (tablets, oral liquid)
Laxatives (bisacodyl, docusate, stercula, lactulose, macrogol, glycerol, sorbitol)
Non-steroidal anti-inflammatories  (extended indication)
Morphine (extended supply)
Methadone (extended supply)
Paracetamol (suppositories and modified release formulations)
Clonazepam (extended indication)
Benzodiazepam derivatives (extended supply)
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the whole process is dependent on there being a sponsor
willing to meet the time, effort and costs required to take
the drug through the various stages. Only the sponsor
(usually a pharmaceutical company) can apply to list a
medicine or change a listed indication on the Australian
Register of Therapeutic Goods.
To commence the process of improved access to
palliative care medications, one of the first tasks the
PCMWG undertook was to identify those drugs that
already met the requirements necessary for PBS listing
or those which could be listed with only minor changes
in indication required. This led to drugs such as
promethazine, hyoscine butylbromide, long-acting
paracetamol and various laxatives quickly coming into
the PBS within the palliative care section. The more
slow and difficult task has been in getting the necessary
approval for a whole range of other medications that
have been identified by the Australian palliative care
community as being of a high priority. 
The Australian Government is supporting this next step
in a number of ways. Significantly, funding has been
made available to set up the infrastructure necessary to
help gather scientific evidence necessary for the
approval process and to support a national clinical trials
network – the Palliative Care Clinical Studies
Collaborative (PaCCSC). The collaborative is comprised
of a number of centres across the country that have a
proven ability to undertake clinical studies. The primary
aim of PaCCSC is to complete a series of multi-site, well
designed controlled clinical trials in order to substantiate
the efficacy (or otherwise) of the palliative care
community’s priority drugs and from there further the
argument for improved access to medications through
the PBS. The current trials in design phase are centred
on ketamine, risperidone, octreotide, ketorolac and
megestrol acetate.
Conclusion
The palliative care section within the Schedule of
Pharmaceutical Benefits reflects a commitment by the
Australian Government to provide affordable and
equitable access to palliative care medicines that have
an established efficacy and proven pharmaco-economic
base. Our responsibility as palliative care physicians is to
improve awareness within the primary healthcare
workforce of existing palliative care medicines listed on
the PBS, encourage our colleagues to use the palliative
care section and to promote quality use of medicines
and best practice prescribing within palliative care. We
must encourage sponsors to consider palliative
indications as part of the registration process on the
Australian Register of Therapeutic Goods and assist
with the gathering of evidence to demonstrate the
quality, efficacy and safety of the medicines we have
prioritised.
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